The present invention is a sealable microampule for storage of environment sensitive material which is autosampler compatible and provides a space, small enough to make low volumes of liquid available for auto-injector needle. The microampule fits inside an autosampler vial and breaks open at a certain height to allow stable accommodation inside the autosampler vial. The microampule has a longer length which provides space to apply the force to snap break the seal at the opening level of the autosampler vial.

Provided is a pre-filled drug package that can inhibit protein aggregation after long-term storage even when accommodating a protein solution formulation having a low non-ionic surfactant concentration. The pre-filled drug package includes a protein solution formulation and a housing accommodating the protein solution formulation. The protein solution formulation has a non-ionic surfactant concentration of not less than 0 mg/mL and less than 0.05 mg/mL. At least part of a section of the housing that is in contact with the protein solution formulation is formed of a resin including either or both of a hydrogenated cycloolefin ring-opened polymer and a copolymer of a cycloolefin and a chain olefin.

A glass container includes a glass body comprising an external surface, an internal surface opposite the external surface, a thickness T extending between the external surface and the internal surface, and an external surface layer extending from the external surface into the thickness of the glass body, wherein the external surface layer has a porosity greater than a porosity of a remainder of the glass body extending from the external surface layer to the internal surface.

A bottle configured to house and dispense items. The bottle comprises a body, a finish positioned above the body, and a ramp protruding into an interior space defined by the body. The body includes a base and a sidewall extending up from the base. The body defines the interior space for housing the items. The finish presents an opening for dispensing the items from the body. The ramp is formed with a concave shape configured to support one or more of the items.

Methods for increasing the hydrolytic resistance of a glass article are disclosed. According to one embodiment, the method includes providing a glass article with a pre-treatment hydrolytic titration value. Thereafter, the glass article is thermally treated at a treatment temperature greater than a temperature 200C less than a strain temperature of the glass article for a treatment time greater than or equal to about 0.25 hours such that, after thermally treating the glass article, the glass article has a post-treatment hydrolytic titration value that is less than the pre-treatment hydrolytic titration value.

The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, RITUXAN (rituximab), AVASTIN (Bevacizumab), LUCENTIS (Ranibizumab) or HERCEPTIN (trastuzumab).

The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, HUMALOG (insulin lispro), HUMALOG MIX 75-25 (insulin lispro), HUMALOG MIX 50-50 (insulin lispro), HUMILIN 70-30 (insulin), HUMILIN N (insulin), HUMULIN R (insulin) or GEMZAR (gemcitabine).

A glass syringe barrel is provided that has an at least partially conically shaped upper portion and a longitudinal axis. The glass syringe barrel has a top end through which a liquid can be ejected and a bottom end into which a plunger stopper can be pushed. The glass syringe barrel includes, in a direction from the top end to the bottom end, a cone, a shoulder region, and a body region. The shoulder region has and outer contour that has a concave and substantially circular arc-shaped area c.sub.1 with an outer radius r.sub.1. The outer contour of the glass syringe barrel in the shoulder region is defined by a certain minimum value the radius of curvature.

Disclosed is an intravenous drug dispensing kit including: a cylinder cartridge for introducing and discharging external fluids through changes in the volume of a cylinder occurring when a pair of first and second pistons disposed therein is fixed and rotates relatively to each other; a first tube connected to an outlet tube of the cylinder cartridge; a three-way valve having a first introducing flow path, a second introducing flow path, and a discharge flow path connected to any one of the first introducing flow path and the second introducing flow path; a second tube for connecting the discharge flow path of the three-way valve to an inlet tube of the cylinder cartridge; a third tube connected to the first introducing flow path of the three-way valve; and a fourth tube connected to the second introducing flow path of the three-way valve.

A sealed pharmaceutical container includes a shoulder, a neck extending from the shoulder, and a flange extending from the neck. The flange includes an inclined sealing surface defining an opening in the sealed pharmaceutical container. The sealed pharmaceutical container also includes a sealing assembly including a stopper extending over the sealing surface of the flange and a cap securing the stopper to the flange. The stopper has a glass transition temperature (T.sub.g) that is greater than or equal to −70° C. and less than or equal to −45° C. The sealing assembly maintains a helium leakage rate of the sealed pharmaceutical container of less than or equal to 1.4×10.sup.−6 cm.sup.3/s as the sealed pharmaceutical container is cooled to a temperature of less than or equal to −45° C.